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JCB: Editorial
Nearly  six  years  ago  Ira  Mellman, 
then Editor-in-Chief of the JCB, pub-
lished an editorial entitled “Provid-
ing realistic access” (1). It described 
the  Journal’s  efforts  to  reconcile  its   
subscription-based  business  model 
with  the  goal  of  providing  public   
access to scholarly journal content. 
Since then, developments in the public- 
access  movement  are  bringing  us 
closer to the ideal of universal public 
access. But will there still be a place 
for  selective  journals  like  the  JCB 
when we achieve that objective?
Selective vs. archival
Mellman’s article considered various pub­
lishing business models in the context of 
editorial selectivity. It made the distinc­
tion between selective journals and archi­
val journals but did not define the terms. 
Traditionally, journals have been defined 
within the parameters of stringent peer 
review, in which reviewers address two 
questions: (i) do the data support the con­
clusions? and (ii) do the conclusions rep­
resent a conceptual advance for the field 
of study? For publication in a selective 
journal like the JCB, the answer to both 
questions must be yes. For publication in 
an archival journal, the answer to only the 
first question must be yes.
Mellman asserted that “in an ideal 
world, all archival journals would switch 
to  open  access,  and  researchers  would 
send more of their best work only to 
the selective journals [which will con­
tinue to have subscription­based business 
models].” He was using the term “open 
access” to refer to the author­pays business 
model, in which the author pays all of 
the publication costs, and the published 
product is available to the public for free 
immediately upon publication. The first 
major  publisher  in  the  biomedical  sci­
ences to develop such a business model, 
BioMed Central, codified its “archival” 
nature. Upon its inception 10 years ago, 
a  BioMed  Central  official  noted  that 
“Reviewers  will  assess  scientific  accu­
racy, not interest.” (2)
BioMed Central is a commercial 
concern,  created  by  a  publisher  who 
foresaw  that  the  success  of  this  form   
of business model is dependent on vol­
ume. To earn sufficient revenue to cover 
operational costs, it is necessary to pub­
lish  many  papers.  This  implies  that   
a large percentage of submissions will   
be accepted.
In 2003, the journal PLoS Biology 
was founded by an idealistic group of sci­
entists who wanted to create a selective   
open­access journal using the author­pays 
business model. On the occasion of the 
journal’s launch, the founders wrote that 
they were entering the publishing busi­
ness “to demonstrate that high­quality 
journals can flourish without charging 
for access.” (3)
Subsidizing selectivity
The cost of online publishing in the JCB 
is  currently  z$10,000  per  published   
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article. The majority of this expenditure 
is on the personnel required for selec­
tive peer review, high quality produc­
tion, and maintenance of data integrity. 
Given the fact that no funding agency 
has indicated it will pay this high cost, 
Mellman  commented  that  “It  is  dif­
ficult to see how the most prominent 
open  access  selective  journal  (PLoS 
Biology) will be financially viable in the 
long run without support from grants or 
other ventures.” This remains true today, 
given their relatively low author charge 
of $2,900 per article. Indeed, even with 
grant  support,  PLoS  did  not  cover  its 
operational costs (4) until they launched 
such an “other venture” in the form of 
PLoS  ONE,  an  archival  journal.  Their 
website  states,  “PLoS  ONE  will  rigor­
ously peer­review your submissions and 
publish all papers that are judged to be 
technically sound. Judgments about the 
importance of any particular paper are 
then made after publication by the read­
ership (who are the most qualified to de­
termine what is of interest to them).” (5) 
In the month of March 2010, PLoS ONE 
published 475 articles at $1,350 per ar­
ticle. The PLoS business model is thus to 
subsidize open access to a group of se­
lective journals with the revenue gener­
ated by the high volume of publication in 
its archival journal.
Is there a way to publish selective 
journals  and  provide  public  access  to 
their content without having to resort to 
this model? There has been much talk 
about a revolution in publishing busi­
ness models, but we have been able to 
provide  public  access  to  the  content   
in our selective journals within the pa­
rameters  of  a  subscription­based  busi­
ness model.
Public access after a  
short delay
The JCB was among the first subscription­
based  journals  to  release  its  content   
to the public six months after publica­
tion. We did this in January 2001, and 
our subscription revenues have grown 
every year through 2009. We did this 
because  we  understand  that  much  of 
our content is generated through pub­
licly  funded  research,  that  many  of   
the  scholars  who  carry  out  peer  re­
view are publicly funded, and that the   
public supports (either directly or in­
directly) many of the institutions that 
buy our subscriptions. We thus feel an   
obligation  to  give  something  back  to 
that public.
Mellman noted that delayed pub­
lic  access  “would  also  be  perfectly 
viable  for  the  for­profit,  top­tier  jour­
nals that currently have little or no free 
content.” However, it has become clear 
that  those  companies  who  enjoy  large 
commercial  gains  from  the  subscrip­
tion model will not voluntarily release 
most  of  their  content  to  the  public, 
even after a short delay. That’s why we   
need mandates.
Mandate, mandate, mandate
The  most  important  development  of 
the past six years in the public access 
movement has been the mandates from 
funding  agencies  and  research  insti­
tutions. The most prominent of these   
is the National Institutes of Health (NIH)   
mandate, which requires that the pub­
lished results of NIH­funded research be 
made accessible to the public within a year 
of  publication.  The  Federal  Research 
Opinion submitted to the Office of Science and Technology Policy Public Access 
Policy Forum, January 20, 2010
(http://www.whitehouse.gov/sites/default/files/microsites/ostp/papf­post­8.pdf)
We at the Rockefeller University Press (RUP) strongly believe in the release of 
scholarly journal content to the public after a short delay under subscription access 
control. As a biomedical research publisher, we understand that much of our con­
tent is generated through publicly funded research, that the peer review process is 
performed in large part by publicly funded individuals, and that a significant por­
tion of subscription revenue is obtained from publicly funded institutions. Like 
RUP, many scientific publishers feel an obligation to give something back to the 
public, and thus they release their content after a short period under subscription 
control. But other publishers are reluctant to do so, and the government has been 
forced to take action. We support the government’s efforts to make the results of 
publicly funded research available to the public after a short delay.
We have released the content of our three biomedical research journals to the 
public six months after publication since January, 2001, and our subscription reve­
nues have grown every year through 2009. We release all of our content, regardless 
of funding source, and we think all funding agencies should mandate this form of 
public access. For biomedical research journal articles, we think six months is a 
reasonable embargo before release to the public.
We strongly believe that only the final, published version of an article should 
be released to the public. Many publishers, however, allow authors to post only the 
authors’ accepted version of a manuscript in a public repository. The notion that 
this restriction will provide an incentive to subscribe is misguided. For both ver­
sions, the most important function of a scholarly publisher—peer review—has   
already been completed. Although there is additional value added through copy 
editing, layout, and proof reading, we believe that these are less important to read­
ers than the validation and prioritization afforded by peer review. Thus, readers are 
likely to read the first version of a peer­reviewed article that is available to them, 
without regard to copy editing, layout, and proof reading. They are unlikely to be 
motivated to subscribe simply for the benefit of these additional features.
We view PubMed Central as a good model for the dissemination of research 
articles by a Federal agency. The administrators of PubMed Central work closely 
with publishers to facilitate submission and display of articles. They honor indi­
vidual publishers embargoes up to the mandated maximum 12­month delay, they 
are willing to host and display the final published version of journal content if it is 
provided by a publisher, and they keep the content updated with corrections and 
retractions. The PubMed Central model could be used for the development of a 
central repository for all federally funded research.395 Updating realistic access • Rossner
Public Access Act, which has been in­
troduced  in  the  U.S.  Congress,  seeks 
to extend this mandate to several other 
Federal funding agencies.
Globally,  numerous  other  govern­
mental  and  private  funding  agencies 
have instituted similar policies or stricter 
ones, which require release to the pub­
lic within six months. Research institu­
tions have also begun mandating such 
public access through their own reposi­
tories. The institutions, however, must 
also respect the need for publishers to 
recoup their costs by providing a short 
embargo  before  releasing  content  to   
the public.
The  issues  of  copyright  to  and 
versioning  of  published  material,  as 
they relate to public access mandates, 
have been considered elsewhere (see [6] 
and text box).
We  at  the  Rockefeller  University 
Press  call  for  all  biomedical  research 
funders  and  institutions  to  mandate 
public  release  of  content  six  months 
after  publication.  We  and  other  non­ 
commercial publishers have shown that 
this is a sufficient delay for selective 
journals to continue selling subscrip­
tions. Researchers need to push for these 
mandates from their own funding agen­
cies and institutions.
A new definition of archival
When  all  biomedical  research  publi­
cations are available to the public, an 
economic layer will be added to the defi­
nition of selective vs. archival. Selective 
journals publish content that can be sold 
in the first six months after publication. 
Archival  journals  publish  content  that 
few people are willing to buy during the 
first  six  months  after  publication,  and 
they have to recoup their costs through 
an author­pays model or some other non­
subscription model.
Currently, librarians pay for archi­
val content that is kept perpetually under 
subscription  access  control.  If  all  bio­
medical research articles were free to the 
public  after  six  months,  and  librarians 
had the ability to choose individual jour­
nals  at  reasonable  prices  (see  7),  they 
would subscribe only to those journals 
with quality content to which their users 
demanded  access  during  the  first  six 
months after publication. But is there 
enough value left in selectivity to pro­
vide this demand?
Valuable content
Has the revolution in searchability ne­
gated the utility of selective journals as 
filters  of  information? That  is,  is  there 
still a value to the stringent peer review 
process  used  by  selective  journals,  or 
should all publications appear in archival 
journals? Mellman commented that “Se­
lective journals prioritize and streamline   
information for busy readers, and pro­
vide a hierarchy—admittedly imperfect— 
for appointments, promotions, and grant 
review.” There is a value to knowing that 
the editors and reviewers of the JCB 
thought that a particular piece of work 
was  a  significant  advance  in  the  field. 
People  are  still  willing  to  pay  for  that 
value. In the words of one observer of the 
scholarly publishing industry, “Charging 
for information is a clear­cut way to know 
how valuable it is.” (8) For biomedical 
research  journals,  I  would  modify  that 
statement to say that “Charging for infor­
mation in only the first six months after 
publication is a clear­cut way to know 
how valuable it is.”
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